-
Stage M2 (2025-2026) : Unravelling the role of hematopoietic cell polarity in Acute Myeloid Leukemia
Institut de la leucémie Paris - INSERM UMR 1342 - Stage - Paris
-
Stage M2 (2025-2026) : Characterization of the molecular effectors involved in the CD8+ T-cell-mediated Graft versus Leukemia (GvL) response in a preclinical model of Acute Myeloid Leukemia (AML).
Institut de la leucémie Paris - INSERM UMR 1342 - Stage - Paris
-
Ingénieur.e en biologie
Abivax - CDD - Montpellier
